Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Dyno Therapeutics logo — We build AI-powered gene therapies.

Dyno Therapeutics

We build AI-powered gene therapies.

Founded 2018 United States Watertown, United States 94 employees Series A Total: $109.00M Biotechnology, Pharmaceutical

General Information

Company Name Dyno Therapeutics
Founded Year 2018
Location United States Watertown, United States
Founders / Decision Makers
Team member
Employees 94
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2B2C, D2C
Revenue Model Licensing, Service Fee
Offices as of Oct 2026
Watertown, United States
Social

BounceWatch is an independent company data service, not affiliated with Dyno Therapeutics. To contact Dyno Therapeutics, visit dynotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Dyno Therapeutics compare?

A PDF of Dyno Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Dyno Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 27, 2026

Dyno Therapeutics is presenting preclinical data on AI-designed AAV capsids at ESGCTHamburg2026.

New Partnership Oct 07, 2026

Dyno Therapeutics announced that its manufacturing partner, PackGene Biotech, Inc., reliably manufactured five Dyno AAV capsids at scale, supporting preclinical gene therapy studies.

Dyno Therapeutics a competitor of yours? Have our desk watch it

About Dyno Therapeutics

Dyno Therapeutics is an innovative player in the biotechnology and pharmaceutical industries, pioneering the development of AI-powered gene therapies. Founded in 2018, the company is committed to building high-performance genetic technologies designed to transform patient lives. Headquartered in the United States, Dyno is strategically positioned within a robust ecosystem of biotech and pharmaceutical development.

The company garnered significant attention with a Series A investment of $100.00M in May 2021. This round was backed by a strong consortium of investors, including CRV, Lux Capital, Obvious Ventures, Casdin Capital, KdT Ventures, Polaris Partners, and Andreessen Horowitz (a16z). This investment underscores the confidence these prominent investors have in Dyno’s potential.

As the company continues to leverage artificial intelligence to develop transformative genetic therapies, it stands poised to revolutionize patient care and deliver significant advancements in the fields of biotechnology and pharmaceuticals.

Business keywords: AI-powered Gene Therapy, High-Performance Genetic Technologies, Machine Learning in Gene Therapy, Gene Vector Design, Adeno-Associated Virus (AAV) Engineering, Cell-Targeting Capsid Proteins, Synthetic Biology, Next-Generation Sequencing (NGS), In Vivo Experimentation, Data Science in Genomics, Genome Editing, Protein Engineering, Biotechnology Innovations, AI in Healthcare, Therapeutic Development

Services & Products

Development of high-performance genetic technologies
AI-driven solutions for genetic advancements
Collaborative partnerships in genetic research

Target Customers

Patients requiring genetic intervention Healthcare providers Pharmaceutical companies seeking genetic solutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $100.00M 7
CRV Lux Capital Obvious Ventures
CRV, Lux Capital +5
01 May 2021
Seed $9.00M 2
CRV Polaris Partners
CRV, Polaris Partners
01 May 2020
Spinout Undisclosed 1
KdT Ventures
KdT Ventures
01 Nov 2018

Latest News

View All
PackGene Demonstrates Reliable, Scalable AAV Manufacturing Across Multiple Dyno® Capsids — PR Newswire
PackGene Demonstrates Reliable, Scalable AAV Manufacturing Across Multiple Dyno® Capsids
PR Newswire Oct 05, 2026
Dyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress... — Business Wire
Dyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle Society
Business Wire Oct 02, 2026
How AI can accelerate R&D for cell and gene therapies — Mckinsey.com
How AI can accelerate R&D for cell and gene therapies
Mckinsey.com Nov 16, 2022

Dyno Therapeutics Alternatives & Competitors

View All Alternatives
Dyno Therapeutics vs
64x Bio
64x Bio United States

Enabling next generation medicines.

Series A
21 employees
Biopharma, Biotechnology
Compare Dyno Therapeutics vs 64x Bio
Dyno Therapeutics vs
Aera Therapeutics
Aera Therapeutics United States

Enabling the next generation of transformative genetic medicines

Series B
88 employees
Biotechnology, Pharmaceutical
Compare Dyno Therapeutics vs Aera Therapeutics
Dyno Therapeutics vs
GenEdit
GenEdit United States

Delivering the potential of genetic medicines

Series A
47 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Dyno Therapeutics

We build AI-powered gene therapies.
Dyno Therapeutics was founded in 2018.
Dyno Therapeutics is headquartered in Watertown, United States.
Dyno Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on AI-powered Gene Therapy, High-Performance Genetic Technologies, Machine Learning in Gene Therapy and Gene Vector Design. Its customers include Patients requiring genetic intervention, Healthcare providers and Pharmaceutical companies seeking genetic solutions.
Dyno Therapeutics has a B2B, B2B2C and D2C business model. Its revenue comes from Licensing and Service Fee.
Dyno Therapeutics has approximately 94 employees.
Dyno Therapeutics has completed 3 funding rounds, raising a total of $109.00M. The latest funding stage is Series A.
Dyno Therapeutics offers: Development of high-performance genetic technologies, AI-driven solutions for genetic advancements, Collaborative partnerships in genetic research.
Top alternatives and competitors to Dyno Therapeutics include 64x Bio, Aera Therapeutics, GenEdit, Sangamo Therapeutics, Inc., Versameb AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dyno Therapeutics and 64x Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dyno Therapeutics, https://bouncewatch.com/company/dyno-therapeutics, updated 8 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout